GYRE Gyre Therapeutics, Inc.
XNAS 4.28 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
GYRE
$4.28
—
What changed
Recent filings, trades and movesKey stats
$4.28
- 52-Week Range
- $3.97 – $9.14
- YTD
- -37.15%
- IV Rank (30D)
- 89.39
- Straddle Price
- $2.85
- P/C Vol Ratio
- 0.60
- Market Cap
- $0.5B
- Open
- $4.26
- Day Range
- $4.23 – $4.29
- Volume
- 5,859
- Prev Close
- $4.23
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.86% |
| Beta vs SPY | 1.74 |
| Cost of Equity (CAPM) | 14.43% (VRP-adj) |
| WACC | 14.69% |
| Volatility Risk Premium | +54.0pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -17.1% |
| Book / Price | 35.5% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 95.1% |
| FCF Margin (TTM) | -13.5% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $6.43 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $5.54 |
| Bollinger Width / SMA20 | 66.3% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
60-Day Conviction
20%
20-Day Fair Value
≈ by Dec 10, 2026
$4.24
α -0.3%
rank 93%
conviction
29%
40-Day Fair Value
≈ by Jan 8, 2027
$4.30
α +1.3%
rank 93%
conviction
46%
60-Day Fair Value
≈ by Feb 8, 2027
$4.22
α -0.7%
rank 93%
conviction
20%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | n/a | 0% | |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $6.43 | 100% | stability 73% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-11 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.5B
- Employees
- 618
- List Date
- 2023-10-31
- CIK
- 0001124105
- Last Earnings
- Nov 5 before open · −9.7% vs ±113.7% expected
- Headquarters
- San Diego, CA
- Homepage
- https://www.gyretx.com
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | -48.00% | -4.08% | 18.80% | -11.09% |
| Feb | -- | 48.81% | 0.26% | 0.37% | 16.48% |
| Mar | -- | -15.06% | -32.46% | -20.43% | -22.65% |
| Apr | -- | -1.58% | 52.26% | 6.22% | 18.97% |
| May | -- | -18.04% | -2.89% | -24.23% | -15.05% |
| Jun | -- | 11.50% | -4.30% | 13.43% | 6.88% |
| Jul | -- | 20.18% | -5.50% | -12.21% | 0.82% |
| Aug | -- | -1.43% | 16.39% | 7.53% | 7.50% |
| Sep | -- | 2.62% | -3.24% | 13.29% | 4.22% |
| Oct | 0.00% | 16.54% | 2.24% | -34.93% | -4.04% |
| Nov | 273.93% | -13.55% | 5.30% | -10.15%* | 63.88% |
| Dec | 9.79% | 2.28% | -7.95% | -- | 1.37% |
| Total | 310.54% | -25.95% | -3.07% | -45.84% | 58.92% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $5.43
SMA 50: $6.38
SMA 200: $6.85
Current: $4.27
EMA 12: $4.86
EMA 26: $5.50
MACD: -0.6390 | Signal: -0.1113
BEARISH
ADX (14): 30.97
TREND
+DI: 15.15
−DI: 35.59
Momentum Oscillators
RSI (14): 34.72
NEUTRAL
Stoch %K: 13.21
Stoch %D: 15.90
Williams %R: -90.42
Volume & Volatility
BB Upper: $7.29
BB Lower: $3.56
NEUTRAL
OBV: -2,379,257
Vol SMA 20: 188,519
Vol ROC: -96.13%
ATR: $0.46
True Range: $0.06
HV 20: 159.4%
HV 30: 132.2%
HV 60: 99.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before GYRE’s Nov 5 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers:
- Bearish momentum signals from MACD
- High volatility indicating increased risk
- Negative sentiment from options market
Primary Risks:
- Potential downside movement due to high volatility and bearish momentum
- Increased risk of sharp moves based on recent volume activity
Investment Thesis:
GYRE is experiencing a bearish trend, driven by negative momentum signals and high volatility. The stock's recent price action has been influenced by increased risk sentiment, leading to a higher probability of further downside movement.
Recent News Sentiment Impact:
No recent news available. The absence of significant news events may contribute to the stock's heightened volatility.
Technical Analysis
Trend Direction: BEARISH (Short-term)
Support/Resistance Levels:
- Short-term support at $6.79 (Bollinger Bands Lower)
- Medium-term resistance at $7.70 (SMA 50)
- Long-term resistance at $8.09 (SMA 200)
Momentum Signals:
- MACD signal is bearish (-0.18 / Signal: -0.06 / Histogram: -0.13)
- RSI interpretation: Neutral (36.86)
Volume Analysis:
- Volume SMA 20 indicates a decrease in buying pressure
- On-Balance Volume (OBV) suggests a strong selling bias
News & Sentiment Analysis
Recent Headlines Summary: No recent news available
Sentiment Assessment: NEUTRAL
Catalyst Identification: None
Market Narrative: The lack of significant news events may be contributing to the stock's heightened volatility.
Risk & Volatility Assessment
Beta Interpretation: HIGH RISK (1.25)
Volatility Regime: HIGH VOLATILITY (0.86)
Options Market Signals:
- IV rank: 76.5% (High)
- Put/Call volume ratio: 0.38 (Bullish sentiment)
Downside Protection:
- Support levels at $6.79 and $7.32 (EMA 12)
- Risk management considerations include stop-loss levels and position sizing
Market Context & Positioning
Sector Performance: GYRE is underperforming its sector peers
Institutional Activity: Volume patterns suggest institutional interest is decreasing
Correlation Analysis:
- R-squared interpretation suggests a high correlation with the market (0.28)
Relative Valuation:
- GYRE is trading within its historical range, suggesting a neutral position
Key Levels & Action Items
Critical Price Levels:
- Support at $6.79 and $7.32 (EMA 12)
- Resistance at $7.70 (SMA 50) and $8.09 (SMA 200)
Breakout/Breakdown Levels:
- Break below $6.79 could trigger further downside movement
- Break above $7.70 could signal a short-term bullish trend
Time-Sensitive Catalysts: None
Risk Management: Consider stop-loss levels at $6.50 and position sizing to manage risk.
This report provides an objective analysis of GYRE's current situation, highlighting the bearish momentum signals, high volatility, and negative sentiment from options market. The report also assesses the risks associated with this stock, including the potential for further downside movement and increased risk due to its high beta.
Generated
News
All GYRE news →
Earnings History
10 of 10 under expected move
Avg Expected Move
73.01%
Avg Actual Move
8.10%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-02-14 | Pre-Market | 170.67% | 39.87% | 0.23x | Within |
| 2024-08-13 | Pre-Market | 60.45% | 2.53% | 0.04x | Within |
| 2024-11-13 | Pre-Market | 35.13% | 9.56% | 0.27x | Within |
| 2025-05-09 | Pre-Market | 45.36% | 0.53% | 0.01x | Within |
| 2025-08-11 | Pre-Market | 59.81% | 1.67% | 0.03x | Within |
| 2025-11-07 | Pre-Market | 39.51% | 1.77% | 0.04x | Within |
| 2026-03-12 | Pre-Market | 58.82% | 6.30% | 0.11x | Within |
| 2026-05-08 | Pre-Market | 69.31% | 5.66% | 0.08x | Within |
| 2026-07-15 | Pre-Market | 77.29% | 3.47% | 0.04x | Within |
| 2026-11-05 | Pre-Market | 113.74% | 9.68% | 0.09x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
GYRE Options Activity & IV Rank
GYRE IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 354.2%
7-DTE IV: 354.2%
Expected Move: $2.85
7-DTE Move: $4.15
Days to Exp: 37 (2026-12-18)
Options Flow · All expiries
Call Volume: 5
Put Volume: 3
P/C Volume: 0.6
BULLISH
Call OI: 6
Put OI: 3
P/C OI: 0.5
Total OI: 9
ATM Options Pricing
ATM Call: $0.45
ATM Put: $2.40
Call %: 10.5%
Put %: 56.1%
Chain Summary
Chain Volume: 8
Chain OI: 9
Last Updated: 11/11/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 94th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
94%
vs own history
GEX tilt
+0.72
OI-weighted, today
Vanna tilt
-0.48
δ-sensitivity to IV
Charm tilt
+0.28
δ-decay vs time
Vanna tilt -0.48: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
? What is this?
· 4 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)48.0MediumNov 11
IV Rank (30 DTE)89.4HighNov 11
Straddle Price (30 DTE)$2.85Nov 11
Beta Analysis
Risk Metrics
Beta: 1.6629
Alpha: -58.87%
Correlation: 0.3394
R-Squared: 11.5%
Stock Volatility: 67.1%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own GYRE
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $122K | #3586 of 3716 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
GYRE Institutional Ownership (13F)
Filings for 2026-06-30 · 19 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 100,299,468 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
GYRE Insider Trading (Form 4)
Latest: 2026-08-04Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-04 | Claire Weston | Director | Grant (A) | +40,000 opt | — | EDGAR | |
| 2026-08-04 | Maxwell Kirkby | Director | Grant (A) | +40,000 opt | — | EDGAR | |
| 2026-06-22 | Weiguo Ye | Chief Operating Officer | Mixed Sell −11,000 · Exer +11,000 |
— | $3.50 | -$60.5K | EDGAR |
| 2026-06-15 | Weiguo Ye | Chief Operating Officer | Mixed Sell −2,800 · Exer +2,800 |
— | $3.46 | -$15.2K | EDGAR |
| 2026-06-11 | Weiguo Ye | Chief Operating Officer | Mixed Exer +20,918 · Sell −20,918 |
— | $3.46 | -$113.2K | EDGAR |
| 2026-06-10 | Ying Luo | Chief Executive Officer | Grant (A) | +120,000 opt | — | EDGAR | |
| 2026-06-10 | Joshua Benjamin Bergmann | GC and Corporate Secretary | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-06-08 | Weiguo Ye | Chief Operating Officer | Mixed Sell −34,976 · Exer +34,976 |
— | $3.50 | -$192.3K | EDGAR |
| 2026-05-27 | Weiguo Ye | Chief Operating Officer | Mixed Exer +7,500 · Sell −7,500 |
— | $3.42 | -$40.1K | EDGAR |
| 2026-05-22 | Weiguo Ye | Chief Operating Officer | Mixed Exer +22,220 · Sell −22,220 |
— | $3.45 | -$120.0K | EDGAR |
| 2026-05-20 | Ping Zhang | Director | Disp (D) | −250,000 opt | — | EDGAR | |
| 2026-05-20 | Weiguo Ye | Chief Operating Officer | Mixed Exer +9,320 · Sell −9,320 |
— | $3.56 | -$52.4K | EDGAR |
| 2026-05-18 | Weiguo Ye | Chief Operating Officer | Mixed Sell −28,680 · Exer +28,680 |
— | $3.77 | -$173.3K | EDGAR |
| 2026-05-07 | Ying Luo | Chief Executive Officer | Sell (S) | −10,315 | $8.04 | -$82.9K | EDGAR |
| 2026-05-06 | GNI USA, Inc. | 10%+ Owner | Other (J) | +2,601,826 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
GYRE Insider Holdings
4 insiders · @ $4.27
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Songjiang Ma | President | 2,806,642 | $11.98M | -$1.56M | 41 | 2025-05-29 |
| 2 | Ying Luo | Chief Executive Officer | 2,575,362 | $11.00M | -$82.9K | 4 | 2026-06-10 |
| 3 | Weiguo Ye | Chief Operating Officer | 703,000 | $3.00M | -$869.9K | 12 | 2026-06-22 |
| 4 | Thomas Wilson Eastling | Chief Financial Officer | 15,000 | $64.0K | $0 | 4 | 2026-05-06 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
GYRE Board & Officers
As of SEC filings through Aug 4, 2026Directors 8
- Ying Luo · since Dec 26, 2022
- Gordon Carmichael · since Oct 30, 2023
- Renate Parry · since Oct 30, 2023
- David M. Epstein · since Aug 6, 2024
- Ping Zhang · since Jan 5, 2025
- Dan Weng · since Aug 18, 2025
- Claire Weston · since Aug 1, 2026
- Maxwell Kirkby · since Aug 1, 2026
Officers 7
- Ying Luo · Chief Executive Officer · listed since May 2026
- Songjiang Ma · President · since Oct 30, 2023
- Thomas Wilson Eastling · Chief Financial Officer · listed since May 2026
- Weiguo Ye · Chief Operating Officer · since Oct 30, 2023
- Yue Xiong · Chief Scientific Officer · since May 4, 2026
- Joshua Benjamin Bergmann · GC and Corporate Secretary · since May 4, 2026
- Jialiang (NMN) Wang · EVP, General Manager · since May 4, 2026
10% owners 2
- GNI Group Ltd. (entity) · since Dec 26, 2022
- GNI USA, Inc. (entity) · since Oct 27, 2023
Changes in the last 10 years (55)
| Aug 1, 2026 | Maxwell Kirkby became a director |
| Aug 1, 2026 | Claire Weston became a director |
| May 7, 2026 | Ying Luo first listed as Chief Executive Officer in an SEC filing |
| May 6, 2026 | Thomas Wilson Eastling first listed as Chief Financial Officer in an SEC filing |
| May 4, 2026 | Yue Xiong became Chief Scientific Officer |
| May 4, 2026 | The company announced the departure of Ruoyu Chen as Chief Financial Officer in an SEC filing |
| May 4, 2026 | Joshua Benjamin Bergmann became GC and Corporate Secretary |
| May 4, 2026 | Jialiang (NMN) Wang became EVP, General Manager |
| Mar 2, 2026 | The company announced the departure of Thomas Wilson Eastling from the board in an SEC filing |
| Mar 2, 2026 | The company announced the departure of Songjiang Ma from the board in an SEC filing |
| Aug 18, 2025 | Dan Weng became a director |
| Aug 5, 2025 | The company announced the departure of Han Ying as Chief Executive Officer in an SEC filing |
| Jan 5, 2025 | Ping Zhang became a director |
| Aug 16, 2024 | Han Ying first listed as Chief Executive Officer in an SEC filing |
| Aug 6, 2024 | David M. Epstein became a director |
| Jul 1, 2024 | Nassim Usman reported in an SEC filing no longer being a director |
| Mar 20, 2024 | The company announced the departure of Rodney L Nussbaum from the board in an SEC filing |
| Mar 20, 2024 | Rodney L Nussbaum became a director |
| Dec 11, 2023 | The company announced the departure of Han Ying from the board in an SEC filing |
| Dec 11, 2023 | The company announced the departure of Charles C Wu from the board in an SEC filing |
| Dec 11, 2023 | The company announced the departure of Charles C Wu as Chief Executive Officer in an SEC filing |
| Nov 22, 2023 | Ruoyu Chen listed as Chief Financial Officer (previously Interim CFO) in SEC filings |
| Oct 30, 2023 | Weiguo Ye became Chief Operating Officer |
| Oct 30, 2023 | The company announced the departure of Seline E. Miller as SVP Finance; Interim CFO & PAO in an SEC filing |
| Oct 30, 2023 | The company announced the departure of Nassim Usman as President & CEO in an SEC filing |
| Oct 30, 2023 | The company announced the departure of Augustine Lawlor from the board in an SEC filing |
| Oct 30, 2023 | The company announced the departure of Andrea Hunt from the board in an SEC filing |
| Oct 30, 2023 | Songjiang Ma became a director |
| Oct 30, 2023 | Songjiang Ma became President |
| Oct 30, 2023 | Ruoyu Chen became Interim CFO |
| Oct 30, 2023 | Renate Parry became a director |
| Oct 30, 2023 | Han Ying became a director |
| Oct 30, 2023 | Gordon Carmichael became a director |
| Oct 30, 2023 | Charles C Wu became a director |
| Oct 30, 2023 | Charles C Wu became Chief Executive Officer |
| Oct 27, 2023 | GNI USA, Inc. became a 10% owner |
| Oct 27, 2023 | GNI Hong Kong Ltd reported in an SEC filing no longer being a 10% owner |
| Dec 26, 2022 | Ying Luo became a director |
| Dec 26, 2022 | Thomas Wilson Eastling became a director |
| Dec 26, 2022 | The company announced the departure of Sharon Tetlow from the board in an SEC filing |
| Dec 26, 2022 | The company announced the departure of Jeanne Y Jew from the board in an SEC filing |
| Dec 26, 2022 | The company announced the departure of Geoffrey M.D. Ling from the board in an SEC filing |
| Dec 26, 2022 | The company announced the departure of Eddie Williams from the board in an SEC filing |
| Dec 26, 2022 | GNI Hong Kong Ltd became a 10% owner |
| Dec 26, 2022 | GNI Group Ltd. became a 10% owner |
| Oct 13, 2021 | Seline E. Miller became SVP Finance; Interim CFO & PAO |
| Sep 9, 2021 | Jeanne Y Jew became a director |
| Jul 12, 2021 | Grant E. Blouse became Chief Scientific Officer |
| Jul 1, 2020 | Clinton Musil became Chief Financial Officer |
| Jan 15, 2020 | Sharon Tetlow became a director |
| Jan 15, 2020 | Geoffrey M.D. Ling became a director |
| Sep 25, 2019 | Fletcher Payne reported in an SEC filing no longer being Chief Financial Officer |
| Aug 30, 2019 | Veronica Cai became Controller |
| Jan 2, 2018 | Eddie Williams became a director |
| Oct 25, 2017 | Andrea Hunt became a director |
Not reported recently (8)
- Grant E. Blouse · Last reported as Chief Scientific Officer in an SEC filing dated Aug 10, 2022
- Errol B Desouza · Last reported as a director in an SEC filing dated Oct 5, 2021
- Howard Levy · Last reported as Chief Medical Officer in an SEC filing dated Aug 11, 2021
- Clinton Musil · Last reported as Chief Financial Officer in an SEC filing dated Apr 26, 2021
- John P Richard · Last reported as a director in an SEC filing dated Mar 13, 2020
- Veronica Cai · Last reported as Controller in an SEC filing dated Mar 13, 2020
- Stephen A Hill · Last reported as a director in an SEC filing dated Sep 6, 2018
- Harold E Selick · Last reported as a director in an SEC filing dated Jan 18, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
GYRE Proposed Insider Sales (Form 144)
Latest: 2026-05-11
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Ye Weiguo | Officer | 300,000 | $2.12M | 2026-05-13 | Futu Securities International(Ho… | — | EDGAR |
| 2025-11-13 | Ye Weiguo | Officer | 548,000 | $4.57M | 2025-11-15 | Futu Securities International (H… | 10b5-1 | EDGAR |
| 2024-07-18 | NASSIM USMAN | Director | 633 | $9.7K | 2024-07-18 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-07-17 | NASSIM USMAN | Director | 3,347 | $51.3K | 2024-07-17 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-07-16 | NASSIM USMAN | Director | 100 | $1.4K | 2024-07-16 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-07-15 | NASSIM USMAN | Director | 4,900 | $69.0K | 2024-07-15 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-07-03 | NASSIM USMAN | Director | 33 | $396 | 2024-07-03 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-07-02 | NASSIM USMAN | Director | 7,767 | $94.0K | 2024-07-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-07-01 | NASSIM USMAN | Director | 12,200 | $148.1K | 2024-07-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-06-28 | NASSIM USMAN | Director | 3,452 | $41.4K | 2024-06-28 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-06
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-05 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-10-22 | Director or officer change | EDGAR |
| 2026-09-01 | Regulation FD disclosure | EDGAR |
| 2026-08-26 | Regulation FD disclosure | EDGAR |
| 2026-08-07 | Earnings results | EDGAR |
| 2026-07-16 | Director or officer change · Regulation FD disclosure | EDGAR |
| 2026-06-16 | Shareholder vote results | EDGAR |
| 2026-06-02 | Regulation FD disclosure | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
22 ETFs hold GYRE
22 shown · $14.91M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $7.6M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.9M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $1.8M | $77.8B | 2026-11-09 |
| 4 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $664,193 | — | 2026-09-30 |
| 5 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.00% | $650,634 | — | 2026-08-31 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.00% | $470,729 | $14.1B | 2026-11-09 |
| 7 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.00% | $193,896 | $14.1B | 2026-11-09 |
| 8 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.02% | $129,942 | — | 2026-06-30 |
| 9 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $118,260 | — | 2026-08-31 |
| 10 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.00% | $81,224 | — | 2026-09-30 |
| 11 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $47,202 | — | 2026-11-09 |
| 12 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.00% | $45,998 | — | 2026-11-09 |
| 13 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.00% | $34,209 | — | 2026-09-30 |
| 14 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $31,619 | — | 2026-11-10 |
| 15 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $8,868 | $3.2B | 2026-11-09 |
| 16 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $5,901 | — | 2026-09-30 |
| 17 | KBFR Innovator U.S. Small Cap Managed 10 Buffer ETF | Innovator | 0.03% | $4,670 | $13.5M | 2026-11-10 |
| 18 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $3,693 | — | 2026-11-10 |
| 19 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $2,758 | — | 2026-11-10 |
| 20 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $1,785 | — | 2026-11-10 |
| 21 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $80 | — | 2026-11-10 |
| 22 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.00% | $17 | — | 2026-11-10 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.09
TTM Revenue
$117.05M
TTM Net Income
$-6.36M
TTM Op. Cash Flow
$4.32M
Quarterly figures (10 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $22.52M | $-8.69M | $-0.10 | $3.18M |
| Q4 '25 | 2025-12-31 | $37.20M | $-1.72M | $-0.02 | $-5.62M |
| Q3 '25 | 2025-09-30 | $30.56M | $3.61M | $0.03 | $4.68M |
| Q2 '25 | 2025-06-30 | $26.77M | $442.00K | — | $2.09M |
| Q1 '25 | 2025-03-31 | $22.06M | $2.70M | $0.03 | $-129.00K |
| Q4 '24 | 2024-12-31 | $27.87M | $-99.00K | $0.00 | $-2.76M |
| Q3 '24 | 2024-09-30 | $25.49M | $1.12M | $0.01 | $1.73M |
| Q2 '24 | 2024-06-30 | $25.23M | $3.53M | $0.01 | $-5.49M |
| Q1 '24 | 2024-03-31 | $27.17M | $7.53M | $0.03 | $2.88M |
| Q4 '23 | 2023-12-31 | $27.15M | $-101.01M | $-1.51 | $3.36M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-08
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.11
P/S
3.64
EV/EBITDA
154.27
EV/Sales
3.32
ROE
-4.6%
ROA
-3.9%
Div Yield
0.00%
FCF Yield
1.01%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$426.27M
as of 2026-11-11
GYRE vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.26T | 46.2 | +45.5% | +31.7% | 30 |
| JNJ Johnson & Johnson | $679.1B | 42.2 | +7.8% | +34.1% | 69 |
| ABBV ABBVIE INC. | $518.4B | 50.2 | +10.7% | +27.3% | 33 |
| MRK Merck & Co., Inc. | $366.7B | 151.3 | +4.9% | +37.9% | 39 |
| NVS Novartis AG | $309.1B | — | — | +15.8% | 40 |
| AZN AstraZeneca PLC | $293.7B | — | — | +102.0% | 1 |
| ABT Abbott Laboratories | $191.4B | 40.8 | +10.0% | −11.4% | 18 |
| NVO Novo-Nordisk A/S | $182.4B | — | — | −22.8% | 16 |
| GYRE Gyre Therapeutics, Inc. Common Stock | $509M | — | +16.3% | −37.3% | 89 |
| Peer median | $337.9B | 46.2 | +10.0% | +29.5% | 32 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.93M
SI % of Float
11.50%
Days to Cover
16.30
Short Vol Ratio
72.5%
Free Float
16.76M
Float %
15.0%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-08-14